In 2021, Choe et al. developed a synNotch CAR-T cell system whose synNotch receptor recognizes a specific priming antigen, such as the heterogeneous but tumor-specific glioblastoma neoantigen epidermal growth factor receptor splice variant III (EGFRvIII). This evidence concerns the gene EGFR and neoplasm.